A backhanded 20-fold target population estimate/concern....by the FDA?!? Versus what Bioniche went in with. What is that informal endorsement of market potential worth in negotiation$ with potential partners? And, HighteawithIntrepid full marks to your logic but I believe you missed a potential 20-fold point in your calculation. A "treatment" does not consist of one dose. Taylor Collison's Feb-11 report estimated Urocidin's "average dosing regimen" at up to 21 doses over 2 years. Tanya Maciver's April-10 had the "average course of therapy" at 15 doses. I would have included the new revenue figure but my calculator keeps showing an error me$$age. Let the "partnering" negotiations now turn up a few notches! rg